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Colorectal cancer (CRC) is one of the most common
cancers worldwide with a peak of incidence in industri-
alised countries. It is a complex disease related to
environmental and genetic risk factors. Low-penetrance
genetic variations contribute significantly to sporadic and
familial form of CRC. Genome-wide association studies
(GWAS) have uncovered numerous robust associations
between common variants and CRC risk; only a few of
those were protein altering non-synonymous polymor-
phisms. One of the hypotheses is that non-coding and
intergenic variants may change the expression levels of one
or several target genes and, thus, account for a fraction of
phenotypic differences, including susceptibility to CRC.
Such genetic variations have been detected as expression
quantitative loci (eQTLs) that show linkage/association to
a large number of genes and have been defined as ‘‘master
regulators of transcription’’. In the present work, we
overview the potentialities to use results from GWAS and
eQTL studies in the identification as well as investigation of
master regulators in CRC susceptibility.
Colorectal cancer
General information
Colorectal cancer (CRC) is one of the most common
malignancies in the world, with particularly high incidence
rates in Western countries (1). Worldwide, there were
estimated 1 230 000 new cases in the year 2008. CRC is also
the third leading cause of cancer death, with an estimated
680 000 deaths reported in 2008 (2). One of the consistent
etiological factors associated with risk of the disease has been
the Western-style diet, a highly caloric and rich in animal fat,
which in combination with sedentary lifestyle constitutes an
extremely high risk factor. Those inferences have been
reinforced by epidemiological studies on migrant populations.
One of the possible explanations for the correlation between
CRC and diet is perhaps direct mucosal contact, in colon and
rectum, with food components and probable exposure to diet-
induced metabolic and physiologic changes (2–6). However,
CRC like other multifactorial diseases is fundamentally driven
and modulated by individual genetic backgrounds that most
likely interact with environmental risk factors and influence
risk at population level.
Colorectal tumours progress through a series of clinical and
histopathologic stages that range from single crypt lesions
(aberrant crypt foci) through small benign tumours (adenoma-
tous polyps) to malignant cancers (carcinomas). The transition
of normal epithelia cells to carcinoma cells has been shown to
involve a series of somatic genetic changes that include
inactivation of tumour suppressor genes as well as oncogenic
activation (7). The major somatic genetic alterations include
activating mutations in K-RAS, inactivation of tumour
suppressor genes on chromosomes 17p (TP53), 5q and 18q
(8). Mutations in K-RAS occur in about 50% of CRC and
in adenomas. Screening of K-RAS mutations constitutes
an integral part of regular diagnosis prior to the treatment of
patients with metastasised disease (9). Somatic mutations in
adenomatous polyposis coli (APC) gene, located on chromo-
some 5q, are present in over 80% of sporadic CRC. Inherited
mutations in the gene are responsible for familial adenomatous
polyposis (FAP) coli, a genetic autosomal dominant disease.
Somatic alterations in the APC gene that occur in sporadic
CRC are similar to inherited truncating mutations in FAP. APC
mutations are the earliest lesion and are, therefore, considered
as gatekeeper event in colorectal tumorigenesis (10).
Genetics of CRC
Colorectal carcinoma is generally classified into three catego-
ries. Familial CRC (around 30% of total CRC cases) refers
to patients with at least one blood relative with CRC or an
adenoma but with no specific germline mutations or clear
pattern of inheritance. The majority, approximately 67% of
CRC cases, are sporadic or show a pattern of familial
aggregation, not fitting into models of Mendelian inheritance
(10). The remaining 3% of CRC patients belongs to cases with
inherited CRC syndromes (11,12). Those are carriers of highly
penetrant germline mutations in cancer susceptibility genes.
The most representative syndromes are the ones characterised
by multiple benign colorectal polyps and others without
polyposis. The first group includes several polyposis syn-
dromes, such as FAP, Peutz-Jegher syndrome, familial juvenile
polyposis. The hereditary nonpolyposis colorectal cancer, also
known as Lynch syndrome, is characterised by germline
mutations in different DNA mismatch repair genes (13).
The complex etiology of sporadic CRC involves a combina-
torial impact of genetic and environmental risk factors (10,14).
Epidemiological studies have identified several risk factors,
including meat, tobacco and alcohol consumption, that
modulate risk of CRC (reviewed in ref. 5). On the other hand,
vegetable consumption, prolonged use of non-steroidal anti-
inflammatory drugs, oestrogen replacement therapy and
physical activity are known as protective factors (5). Other
significant etiological factors are chronic inflammatory bowel
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diseases and a positive family history of CRC. Population-
based studies showed that ulcerative colitis results in a 20-fold
increased incidence of CRC and a 4.4-fold increase in
mortality, while Crohn’s disease causes 3-fold increase in the
risk of colorectal malignancies (15,16). Family history is
established to be one of the strongest risk factors for the
development of the disease, as almost 30% of the individuals
report a positive family history (17).
It had been long hypothesized and subsequently shown
experimentally that low-penetrant genetic variants are
probably causal for the inter-individual variation in suscep-
tibility to CRC. CRC, as most of forms of human cancers,
shows complex inheritance in the general population.
Contributors to these complex patterns can be combination
of genetic variants with common-to-rare frequency and low-
to-intermediate penetrance (18). Although estimated
inherited susceptibility accounts for about 35% of variance
in CRC risk, high-penetrant germline mutations account for
only 6% of cases (19,20). Much of the remaining variation in
genetic risk is likely to be a consequence of the co-
inheritance of multiple low-penetrance variants, which are
common in general population. The ‘‘common-disease
common-variant’’ model of CRC implied that association
analyses based on scans of polymorphic variants should be
a powerful strategy for identifying low-penetrance suscepti-
bility alleles (14). While the association studies based on
a candidate gene approach did identify some variants
involved in CRC susceptibility, but success of such
investigations remained limited and many times results were
not reproducible by independent studies. Recent meta-
analyses of various candidate-gene based case-control studies
have provided limited support for the role of variants in
the MTHFR, CCND1, GSTT1, XPC, NQO1 and NAT2 genes
(21–27).
GWAS, genetic expression variation and CRC
The advent of so-called genome-wide association studies
(GWAS) has resulted in robust identification of genetic
variants associated with susceptibility of various complex
diseases. Several GWAS have also been applied to investigate
the impact of common genetic variations on CRC susceptibility
(28–43). So far, various chromosomal loci have been shown to
modestly increase CRC risk (Table I) (28–36,41,43). The
identified variants, with minor allele frequencies between 7 and
90%, have been shown to increase risk of CRC with allelic
odds ratios , 1.3 (44). Though, the individual associated
variants identified through GWAS impart only a modest risk of
CRC, the population attributable fractions have been shown to
be significant because of substantial minor allele frequencies.
Moreover, through the possibility of a concerted effect, the
variants can potentially influence an individual’s risk of
developing CRC significantly (14). Based on the location
within the genome, most of the identified associated single-
nucleotide polymorphisms (SNPs) cannot be per se causal but
rather indicate the possibility of being in linkage with the
‘‘real’’ causal variants. Nevertheless, the role of some of the
associated variants in transcription either through cis- or trans-
regulation remains plausible as indicated by several inves-
tigators (45–48). In one such study, it has been shown that
a variant at chromosome 8q23.3 may influence the transcrip-
tional regulation of eukaryotic translation initiation factor 3H
(EIF3H), providing support for the functional significance of
the variant and observed association with CRC (46). This class
Table I. SNPs associated with risk of CRC identified and validated through GWAS
Polymorphism Chromosome Locus/genes (major/minor alleles)a References Cases/controlsb ORc 95% CId P-value
rs16892766 8q23.3 EIF3H (A/C) Tomlinson et al. (36) 922 (17872)/927 (17526) 1.27 1.20–1.34 3  1018
rs 10795668 10p14 Intergenic (G/A) Tomlinson et al. (36) 922 (17872)/927 (17526) 1.12 1.10–1.16 3  1013
rs6983267 8q24.21 c-MYC (G/T) Tomlinson et al. (36) 922 (17872)/927 (17526) 1.24 1.17–1.33 7  1011
Tomlinson et al. (30) 930 (7334)/960 (5246) 1.27 1.16–1.39 1  1014
Zanke et al. (31) 1257 (6223)/1336 (6443) 1.17 1.12–1.23 3  1011
Cui et al. (41) 1583 (4809)/1898 (2973) 1.18 1.11–1.25 2  108
rs 4939827 18q21.1 SMAD7 (T/C) Broderick et al. (28) 940 (7473)/965 (5984) 1.16 1.09–1.27 1  1012
Tenesa et al. (35) 981 (16476)/1002 (15351) 1.2 1.16–1.24 8  1028
Tomlinson et al. (36) 922 (17872)/927 (17526) 1.18 1.10–1.25 2  106
rs4779584 15q13.3 GREM1/SCG5 (C/T) Tomlinson et al. (36) 922 (17872)/927 (17526) 1.23 1.14–1.34 5  107
rs3802842 11q23.1 C110rf93 (A/C) Tenesa et al. (35) 981 (16476)/1002 (15351) 1.11 1.08–1.15 6  1010
rs4444235 14q22.2 BMP4 (T/C) Houlston et al. (32) 1902 (4878)/1929 (4914) 1.11 1.08–1.15 8  1010
rs9929218 16q22.1 CDH1 (G/A) Houlston et al. (32) 1902 (4878)/1929 (4914) 1.10 1.06–1.12 1  108
rs10411210 19q13.11 RHPN2 (C/T) Houlston et al. (32) 1902 (4878)/1929 (4914) 1.15 1.10–1.20 5  109
rs961253 20p12.3 Intergenic (C/A) Houlston et al. (32) 1902 (4878)/1929 (4914) 1.12 1.08–1.16 2  1010
rs10936599 3q26.2 MYNN (C/T) Houlston et al. (38) 3334 (14851)/4628 (15569) 1.04 1.04–1.10 3  108
rs6687758 1q41 DUSP10 (A/G) Houlston et al. (38) 3334 (14851)/4628 (15569) 1.09 1.06–1.12 2  109
rs4925386 20q13.33 LAMA5 (C/T) Houlston et al. (38) 3334 (14851)/4628 (15569) 1.08 1.05–1.10 2  1010
rs11169552 12q13.12 LARP4/DIP2 (C/T) Houlston et al. (38) 3334 (14851)/4628 (15569) 1.09 1.05–1.11 2  1010
rs6691170 1q41 DUSP10 (G/T) Houlston et al. (38) 3334 (14851)/4628 (15569) 1.06 1.03–1.09 1  109
rs7758229 6q25.3 SLC22A3 (G/T) Cui et al. (41) 1583 (4809)/1898 (2973) 1.28 1.18–1.39 8  109
rs7014346 18q24.21 POU5FIP1/HsG57825/DQ515897 (G/A) Tenesa et al. (35) 981 (16476)/1002 (15351) 1.19 1.15–1.23 9  1026
aThe risk allele for each SNP is highlighted in bold. EIF3H, eukaryotic translation initiation factor 3, subunit H; c-MYC, v-myc avian myelocytomatosis viral
oncogene homologue; SMAD7, SMAD family member 7; GREM1, gremlin 1; SCG5, secretogranin V; C110rf93, chromosome 11 open reading frame 93; BMP4,
bone morphogenetic protein 4; CDH1, E-cadherin; RHPN2, Rho GTPase binding protein 2; MYNN, myoneurin; DUSP10, dual specificity phosphatase 10; LAMA5,
laminin alpha 5; LARP4, La ribonucleoprotein domain family, member 4; DIP2, DIP2 disco-interacting protein 2 homologue A (Drosophila); SLC22A3, solute
carrier family 22 (extraneuronal monoamine transporter), member 3; POU5FIP1/HsG57825/DQ515897, hypothetical LOC727677.
bIn brackets are numbers of individuals used for validation part.
cOR, odds ratio.
d95% CI, 95% confidence interval.











of susceptibility variants has been suggested to be of potential
public health importance, allowing risk stratification within
populations (14). The identification of new risk variants may
also be helpful in characterising, more specifically, new cancer
pathways that may lead to new prevention or treatment
strategies for CRC (14).
Despite remarkable success of GWAS in identifying disease-
associated loci, a gnawing gap remains in understanding the
mechanism that leads to the associated increased risk. The
genetic risk may be probably due to both highly prevalent loci
with very modest effect sizes and rare loci with strong effect
sizes (49). There have been, so far, only some rare examples in
which the observed pattern of genetic association corresponded
to a functional candidate variant with a precise localisation of
the functional locus. In the majority of GWAS, regional
linkage disequilibrium extends across multiple genes and the
disease-associated variants serve as proxies for unrecognised
non-coding variation, precluding claims of disease-specific
gene identification (50). Another common feature character-
ising GWAS is that many disease-linked SNPs identified to
date are located within introns or inter-genic regions of human
genome, which have no direct relations to known protein-
coding genes or microRNA genes (51). It has been correctly
suggested that the biological interpretation of GWAS signal is
daunting. Candidate loci fall either in gene deserts or in regions
with equally plausible causative genes (52). Thus, non-
canonical mechanisms of phenotype-altering effects of genetic
variations cannot be ruled out. For example, Glinskii et al.
proposed that inter-genic DNA sequence variations associated
with human disorders may affect phenotypes through trans
action via non-protein-coding SNP sequence-bearing RNA
intermediates (51,53). An alternative approach to solve these
problems and to reduce costs associated with GWAS and to
overcome limitations of multiple testing corrections and sample
size is to select SNPs on basis of a functional effect, such as
changes in gene expression levels (52,54–56).
Expression quantitative trait loci studies: a way to mapping
DNA variants that influence gene expression
The levels of expression of different genes vary among
individuals and contribute to phenotypic diversity and
differences in disease susceptibility (57). It has been shown
that several chromosomal regions contain germline determi-
nants that regulate gene expression phenotypes (58). The
quantitative differences in gene expression might be re-
sponsible for a large source of natural variation in
populations, as well as crucial in accounting a large fraction
of phenotypic variability (59,60). Variable gene expression
levels among individuals can be analysed like other
quantitative phenotypes (61). Functional genomics, in
particular expression quantitative trait loci (eQTL) studies,
are useful for determining relationship between sequence
variation in human population and phenotypic diversity (62).
The main goal of eQTL studies in humans has been the
identification of DNA variants (polymorphisms) that in-
fluence the expression levels of genes (also defined as gene
expression phenotype). The basic idea is that sequence
variation may be crucial in affecting the steady-state level of
mRNA molecules of a particular gene in a specific cell type or
tissue. eQTLs studies have led to interesting results for the
identification of regulatory regions and DNA sequence
variants that may modulate levels of expression of genes in
a range of organisms. Interestingly, eQTL studies could fill in
the gaps in understanding the causal reasons for the association
of loci with the disease identified through GWAS (Figure 1)
(63).
eQTL studies connect variation at DNA level with the
quantitative variation in RNA transcription (61). Over 15
million SNPs have been identified so far and while some of
those are functional, the majority is most probably neutral (64).
eQTL studies simplify the search for functional variants that
regulate gene expression through scan of genome for regulators
of gene expression without the need for a priori knowledge of
regulatory mechanisms (61). Gene expression levels are
controlled by a combination of cis- and trans-acting regulators.
Gene expression variation may also be considered a possible
candidate to establish a link between DNA sequence variability
and clinical phenotypes (65). This represents a paradigm shift
from the traditional point of view about the role of genes in the
susceptibility to human diseases as an effect of their variability
in the sequence.
Several disease-linked associations with significant eQTLs
have emerged and such studies have also been extended to
cancer susceptibility (63). eQTLs and gene expression differ-
ences have been evaluated to elucidate the causal relation
between validated SNPs identified through GWAS and the risk
of lung cancer in never smokers (66). Out of 44 candidate
SNPs identified that might alter lung cancer risk in the latter,
only one was replicated in four independent studies. From the
eQTL analysis, the investigators observed a strong correlation
between genotypes of the replicated SNP and the transcription
levels of GPC5 gene in normal lung tissues, showing that
genetic variants at a specific locus (13q31.3), associated with
susceptibility to lung cancer in never smokers, alter the
expression of GPC5 (66).
Out of 14 loci associated with susceptibility to CRC,
discovered through various GWAS, identification of the causal
variants and putative functionalities for some have been
attempted. In one such study, investigators fine mapped the
risk-associated region, identified earlier through GWAS, for
identification of functional variants (47). In the three fine-
mapped regions, a cluster of SNPs within the narrow areas
showed stronger signals for association with the CRC risk than
the surrounding GWAS identified SNPs. Using an eQTL
browser, some of the top associated variants in the regions
analysed have shown an association with different transcript
levels (47). Interestingly, some of the genes previously
proposed as best candidates in those blocks (EIF3, CDH1
and RHPN2) showed no association with different eQTLs.
Those genes had been originally selected because of their
putative involvement in CRC tumorigenesis and vicinity to the
risk-associated tagSNPs. On the other hand, a SNP in an intron
of ZFP90 was found to be associated with CRC risk and with
different transcript levels of the gene. Similarly, UTP23
appeared to be a possible target of the genetic variation
associated with CRC in the 8q23.3 region (47). However, it is
still difficult to draw too many conclusions for now, since
eQTL data sets are not available specifically for colorectal cells
and the observed associations have been detected only in blood
cells. It is possible that implementation of expression studies in
colorectal mucosa could clarify the functionality of the SNPs
associated with the CRC risk. In fact, most eQTL studies,
currently, are conducted on lymphoblastoid cell lines, which do
have some utility for the interpretation of human disease
associations, particularly with immunity-related phenotypes
(52). At the same time potentiality of artefacts associated with











immortalisation, subsequent passage, and growth conditions
prior to harvest cannot be precluded (67).
Hotspots or master regulators
It is likely that genetic variation within a gene, encoding
a transcription factor with multiple targets, can potentially
influence expression of most of its target genes. Such variations
are of particular biological interest, which can be, in principle,
used to identify groups of genes that are controlled by
a common transcription factor (68). The term ‘‘master
regulators’’ has been applied to those genetic variants that
have been detected as eQTL and which show linkage/
association to a large number of genes (58). One of the
common features observed in studies of transcript expression is
the presence of hotspots, that is the individual loci that affect
a large number of transcripts (69). Hotspots or ‘‘master
regulators of transcription’’ are defined as the loci for which
the number of associated transcripts exceeds the expected,
based on assumption of random distribution along the genetic
map (58,70). The description of master regulators is currently
not uniform. One approach takes into consideration the number
of expression traits that best map to a genetic marker regardless
of statistical significance at the whole-genome level (71). Other
studies have divided the genome into bins and then counted the
number of significant linkages within each bin (58,72–74).
Another study divided the autosomal genome of lymphoblas-
toid cell lines into 491 windows of 5Mb and determined the
number of regulators mapping to each window (71). Assuming
random distribution across the genome of phenotype regu-
lators, the probability of finding six or more hits per window
would be very low. On the contrary, in that study, investigators
found two hotspots with six or more hits. In others studies, the
number of whole-genome significant linkages at each marker
have been counted to identify transcriptional master regulators
(70,75,76). In one study, two different linkage strategies to
localise master regulators of transcription were applied. One
strategy involved classical-variance components with use of
information from grandparents and the other based on a linkage
method by regression with floating variable selection that
allowed testing linkage models with combinations of genetic
locations. The former method identified 11 hotspots and the
latter 17 with an overlap of five hotspots (71).
Studies in yeast and other organisms have identified hotspots
that contain genetic variants that influence multiple expression
phenotypes (reviewed in refs. 61 and 77). Human studies, thus far,
have shown less uniform results. The presence of master regulatory
regions has been either reported (58,78) or not (54,79–82).
Surprisingly, only very few verified hotspots have been identified.
The majority of the results indicate a large abundance of local
eQTLs that coincide with the position of the gene and are
presumably cis-acting polymorphisms in the promoter region.
Genetic variants in hotspots, due to their characteristics, are
expected to act more in a trans manner than observed. It is likely
that the differences among studies are partly because of differences
in power to detect trans-acting variants. Distal eQTLs are more
difficult to be identified. It is probable that indirect regulation
mechanism results in reduced statistical power that limits the
reliable detection of hotspots (77,83).
The mechanism of gene expression regulation by master
regulators, identified thus far, currently can be at the best
speculated. The target genes with phenotypes that map to the
same hotspots often share similar functions or reside close to
each other. As genes that share functions are often co-
regulated, their polymorphic regulators would appear as
hotspots in eQTL studies. The expression levels of co-
Fig. 1. Integration between GWAS and eQTL mapping in cancer susceptibility studies (modified from ref. 63).











regulated genes frequently show significant correlations that
may be biologically important. But sometimes the number of
phenotypes mapping to hotspots can be overestimated (84).
Despite instances of false positive associations, some of the co-
mapped clusters have been experimentally verified. Cyclin H
was validated as a new upstream regulator of cellular oxidative
phosphorylation as well as a transcriptional regulator of genes
comprising a hotspot (85). Similarly, other studies have
reported identification of causal regulators and hotspots
(51,86,87).
The distant eQTLs and their hotspots, from the reported
studies, seem to be scarce and are difficult to identify; those
already reported need to be interpreted with caution. The rarity of
hotspots may be due to the limited power of the initial studies but
could also be attributed to factors that have been hypothesized
over the years (77,88,89). In fact, it might be that biological
systems are robust against subtle genetic perturbation that the
majority of heritable gene expression variations is ‘‘buffered’’
and does not lead to the downstream effects on other genes or
phenotypes. Phenotypic buffering of protein-coding polymor-
phisms has been already documented and it represents a general
property of complex gene-regulatory networks (90–92). Most
likely, common alleles are predominantly buffered by the robust
properties of the system and then largely ‘‘neutral’’ for the rest of
the molecules in the system. This scenario may have profound
consequences for the design and interpretation of eQTL studies
in relation to complex disease such as cancer. It could turn out
that these complex diseases are not necessarily the result of
common small-effect variants in a large number of genes but are
rather caused by changes at a few crucial fragile points of the
system (hotspots), which cause large, system-wide disturbances
(93,94). The explanation of the rarity of eQTL master regulatory
loci needs to be elucidated in future studies.
Conclusions
The complexity of CRC like other cancers has made un-
derstanding of underlying genetic factors difficult. The success
of GWAS in identifying various genetic loci associated with the
disease has opened new avenues from the perspective of
understanding the genesis of the disease and its prevention and
treatment. However, a gap in understanding the role of identified
variants through GWAS remains to be fulfilled before any
practical utility. Those identified variants being associated with
expression regulation through cis- and trans-action remains
a probability. Scarcity of information available about master
regulators of expression and cancer risk association is mainly
due to the difficulties in performing eQTL studies on cell lines
other than the lymphoblastoid ones. eQTL studies may be
a powerful tool for clarifying the role of candidate loci identified
in GWAS. Master regulators can be more pertinent to provide
information about the loci widely involved in the disease risk
and in an extension also about the target genes and therefore,
legitimate targets for future investigations.
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